SCH66336
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for SCH66336, covering 2018-10-29 to 2018-10-30. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) [Phase 2]